Agitation Should Be Called Nonspecific Symptom Across Diseases - Lilly
Executive Summary
Agitation should be defined as a nonspecific symptom across a range of disease states, Lilly Zyprexa Product Team Leader Alan Breier, MD, proposed at a March 9 meeting of the FDA Psychopharmacologic Drugs Advisory Committee.
You may also be interested in...
Lilly Zyprexa IM Agitation Use Should Be Limited To Patients Studied In Trials
Lilly's antipsychotic Zyprexa intramuscular injection is safe and effective for the treatment of agitation in schizophrenia, bipolar I disorder and dementia, FDA's Psychopharmacological Drugs Advisory Committee concluded in a unanimous vote Feb. 14.
Lilly Zyprexa IM Agitation Use Should Be Limited To Patients Studied In Trials
Lilly's antipsychotic Zyprexa intramuscular injection is safe and effective for the treatment of agitation in schizophrenia, bipolar I disorder and dementia, FDA's Psychopharmacological Drugs Advisory Committee concluded in a unanimous vote Feb. 14.
Alzheimer's Psychosis Studies Should Measure Improved Functional Status
Studies of drugs for psychosis related to Alzheimer's disease should measure improvement in patients' functional status as well as amelioration of symptoms of psychosis, FDA's Psychopharmacologic Drugs Advisory Committee agreed at its March 9 meeting.